Lloyd Klickstein, Versanis Bio CEO
August 31, 2021 07:00 AM EDTUpdated 07:29 AM
Financing
Startups

A No­var­tis castoff drug gets new life at an At­las-backed start­up look­ing to blaze a trail in obe­si­ty

Kyle Blankenship

Af­ter decades of fail­ure, the obe­si­ty field is fi­nal­ly see­ing some ma­jor progress with the suc­cess of a sta­ble of GLP-1 di­a­betes drugs show­ing clin­i­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times